Cardiff Oncology Inc (CRDF)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib...

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...

Form 8-K - Current report

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...

Form 8-K - Current report

Form 8-K - Current report

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]